New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling HPV-associated cancers led
A groundbreaking new study led by University of Minnesota Twin Cities researchers from both the College of Science and Engineering and the Medical School shows for the first
A new study of patients with Multisystem Inflammatory Syndrome in Children (MIS-C), a rare but severe complication of COVID-19 in children, reveals distinct immune features of COVID-19 not
Caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic continues to spread across the globe. The rise to dominance of
NYU Oral Cancer Center has been awarded a five-year, $3.1 million grant (R01 CA231396) by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
Biologists from RUDN University confirmed that a well-known spasmolytic drug called hymecromone can suppress the inflammatory response in astrocytes, important glial cells of the central nervous system. Potentially,
In people with central nervous system (CNS) lymphoma, cancerous B cells–a type of white blood cell–accumulate to form tumors in the brain or spinal cord, often in close
The upcoming webinar 'Visualizing Human Stem Cell Dynamics by Multicolor, Multiday High-Content Microscopy' will take place on February 17, 11 AM EST / 5 PM CET. Professor Dr.
Imagine a day when clinicians treating people with blood diseases such as leukemia or multiple myeloma can send in requests for laboratories to custom-produce specific types of blood
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. ROFERON-A 170927 Pre Filled Syringes contains the active ingredient interferon alfa-2a (rbe) Consumer Medicine Information
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok
